NEW ZEALAND GAZETTE

No. 83

2012

rank of Ensign (on prob.), with seniority and effect from 1 July 1997.

The following to be Ensign (on prob.) with seniority and effect from 1 July 1997:

Peter Ian Bowmar, OSEA.
Charmaine Mary Carroll, OSC.
Andrea Claire de Thierry, OSEA.
Stephen Phillip Humm, OSEA.
Kim Lorraine Jenkin, ASC.
Lisa Michelle Ramm, OSEA.
Bruce Gordon Warrender, OSC.

INACTIVE LIST OF THE ROYAL NEW ZEALAND NAVAL VOLUNTEER RESERVE

Lieutenant Christopher John Lyne, v.R.D., B.SC., is placed on the Retired List of the RNZNVR with effect from 19 March 1996.

Dated at Wellington this 28th day of July 1997.

PAUL EAST, Minister of Defence.

go5366

Health

Medicines Act 1981

Classification of Medicines

Pursuant to section 106 (1) of the Medicines Act 1981, I, Neil Kirton, Associate Minister of Health, hereby declare the following:

1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines.
3. The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are—

(a) Preparations and admixtures containing any proportion of any substance listed in the notice.
(b) Salts and esters of any substance listed in the notice.
(c) Preparations or extracts of biological materials listed in the notice.
(d) Salts or oxides of elements listed in the notice.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

atorvastatin
irinotecan
letrozole
olanzapine
ropinirole
stavudine

Schedule 2

Restricted Medicines

hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; in rectal medicines containing 1% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of not more than 35 grams of cream or ointment per container or 12 suppositories per pack.

Schedule 3

Pharmacy-only Medicines

amethocaine: for topical use in medicines containing more than 2%
azelastine: for nasal use
etofenamate

lithium: for dermatological use in medicines containing 1% or less

paracetamol: in suppositories; in liquid form; in tablet, capsule or powder form containing 500 milligrams or less and in packs containing more than 10 grams; in powder form containing more than 500 milligrams but not more than 1000 milligrams per sachet and not more than 10 grams per pack.

Dated this 5th day of August 1997.

NEIL KIRTON, Associate Minister of Health.

go5433

Inland Revenue

Income Tax Act 1994

Notice of Determination of Tax Depreciation Rates

Pursuant to section EG 14 of the Income Tax Act 1994, notice is hereby given that the Commissioner of Inland Revenue Department has issued “Determination DEP27: Tax Depreciation Rates General Determination Number 27”, pursuant to section EG 4 of the Income Tax Act 1994. The determination may be cited as “Determination DEP27: Tax Depreciation Rates General Determination Number 27”.

Determination DEP27 will appear in Inland Revenue’s Tax Information Bulletin, Vol. 9, No. 8 of August 1997.

A copy of the determination is available from Inland Revenue offices.

Dated at Wellington this 29th day of July 1997.

JEFFREY TYLER, Assistant General Manager (Adjudication & Rulings).

go5350

Tax Administration Act 1994

Notice of Product Ruling

1. This is a notice of a product ruling made under section 91F of the Tax Administration Act 1994.

2. Product ruling No. 97/60 was issued on 29 July 1997. It relates to a superannuation scheme, and the application of sections HH 3 (5) and JB 3 and the definition of “qualifying trust” in section OB 1 of the Income Tax Act 1994, as amended by the Taxation (Core Provisions) Act 1996. It is essentially the same as product ruling No. 95/14, but takes into account the coming into force of